Search
Nylidrin
go.drugbank.com/drugs/DB06152ApprovedWithdrawnNylidrin is a peripheral vasodilator. … FDA has considered nylidrin as "lacking substantial evidence of effectiveness" in cerebral ischemia, cerebral arteriosclerosis, and other cerebral circulatory insufficiencies.
Nelistotug
go.drugbank.com/drugs/DB19334InvestigationalNelistotug is under investigation in clinical trial NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-line Treatment in Participants With PD-L1 Positive Recurrent/metastatic Squamous … Cell Carcinoma of the Head and Neck- GALAXIES H&N-202).
Adagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigational[A254052] In a phase I/IB clinical study that included patients with KRAS<sup>G12C</sup>-mutated advanced solid tumors (NCT03785249), adagrasib exhibited anti-tumor activity. … KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations.
Danicopan
go.drugbank.com/drugs/DB15401ApprovedInvestigational[A263506] It was subsequently approved by the FDA in March 2024.[L50386] … [L50381] It was first approved in January 2024 in Japan for patients with PNH,[A263506,L50416] shortly after which the EMA adopted a positive opinion and recommended granting it marketing authorization
Synonyms: (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide, (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamideSulfadoxine
go.drugbank.com/drugs/DB01299ApprovedInvestigationalWithdrawnA long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.
Ketoconazole
go.drugbank.com/drugs/DB01026ApprovedInvestigational[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. … Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.
Amsacrine
go.drugbank.com/drugs/DB00276ApprovedInvestigationalWithdrawnIt is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. … It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression and cardiotoxic effects.
Categories: Compounds used in a research, industrial, or household settingProducts: Amlyo 75 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Amsidyl 75 mg/1,5 ml Konzentrat und Lösungsmittel für ein Konzentrat zur Herstellung einer InfusionslösungAlmasilate
go.drugbank.com/drugs/DB13595ApprovedAlmasilate is a buffering antacid that has been used in peptic ulcers and dyspepsia. … However its therapeutic efficacy is not comparable to other approved antacids, as it is no more effective in neutralizing acid and binding bile salts than other conventional antacids [A27138].
Onasemnogene abeparvovec
go.drugbank.com/drugs/DB15528ApprovedInvestigationalOnasemnogene abeparvovec is the first gene therapy that was approved for this indication in the USA. … [Nusinersen] is another gene therapy that is currently approved by the FDA for the treatment of SMA in pediatric and adult patients.
Efgartigimod alfa
go.drugbank.com/drugs/DB15270ApprovedInvestigational[A243759,A243784] Efgartigimod alfa is a first-in-class[L39501] antagonist of the neonatal Fc receptor (FcRn) used in the treatment of MG. … and a reduction in electrical nerve impulses.